首页> 外文期刊>European journal of clinical microbiology and infectious diseases: Official publication of the European Society of Clinical Microbiology >Evaluation of a novel rapid one-step monoclonal chromatographic immunoassay for detection of Helicobacter pylori in stool from children.
【24h】

Evaluation of a novel rapid one-step monoclonal chromatographic immunoassay for detection of Helicobacter pylori in stool from children.

机译:评价一种新型的快速单步单克隆色谱免疫测定法,以检测儿童粪便中的幽门螺杆菌。

获取原文
获取原文并翻译 | 示例
       

摘要

A new rapid office-based one-step monoclonal immunoassay (RAPID Hp StAR, DakoCytomation, Cambridge, UK) for detection of Helicobacter pylori antigen in stool was evaluated in children against invasive diagnostic methods and compared to the results of a monoclonal EIA targeting the same antigen (Amplified IDEIA Hp StAR, DakoCytomation, Cambridge, UK). Coded stool samples from 118 symptomatic children (0.3-18.8 years) were investigated prior to any anti-H. pylori therapy. Fifty-four children were H. pylori infected defined by positive culture and/or two other positive tests ((13)C-urea breath test, histology, rapid urea test), the remaining 64 children showed concordant negative results. Thirty-four infected children (4.8-17.8 years) were monitored with (13)C-urea breath test (five remained positive) and stool test 6-8 weeks after anti-H. pylori therapy. The immunoassays were independently read by two investigators. The monoclonal EIA showed excellent sensitivity and specificity before (98% and 100%, respectively) and after therapy (100%; 96.2%). The rapid immunoassay was invalid for technical reasons in nine samples (5.9%). The two observers agreed in 31 positive and 93 negative results, but had discordant results in 17 samples (11.2%). Overall, the rapid test showed a poor sensitivity (63.8%-71.1%), but a good specificity (91.1%-96.2%) before treatment. We conclude that the new office based monoclonal enzyme immunoassay for diagnosis of H. pylori should be modified to improve sensitivity, inter-observer-variability and some technical problems. In contrast, the monoclonal EIA stool test is highly reliable, both pre- and post therapy, and equivalent to the (13)C-urea breath test.
机译:在儿童中针对侵入性诊断方法评估了一种新的基于快速办公室的一步法单克隆免疫测定法(RAPID Hp StAR,DakoCytomation,英国剑桥),用于检测粪便中的幽门螺杆菌抗原,并将其与针对相同目标的单克隆EIA结果进行比较抗原(扩增的IDEIA Hp StAR,DakoCytomation,英国剑桥)。在进行任何抗H之前,对118名有症状儿童(0.3-18.8岁)的编码粪便样本进行了研究。幽门螺杆菌疗法。通过阳性培养和/或其他两项阳性测试((13)C-尿素呼气试验,组织学,快速尿素测试)定义的54例幽门螺杆菌感染儿童,其余64例儿童表现出一致的阴性结果。抗H后6-8周用(13)C尿素呼气试验(五个仍为阳性)和34个粪便试验监测了34例感染儿童(4.8-17.8岁)。幽门螺杆菌疗法。免疫测定由两名研究人员独立读取。单克隆EIA在治疗前(分别为98%和100%)和治疗后(分别为100%,96.2%)显示出极好的敏感性和特异性。由于技术原因,快速免疫分析在9个样品(5.9%)中无效。两位观察员同意31例阳性结果和93例阴性结果,但17个样本的结果不一致(11.2%)。总体而言,快速测试显示治疗前敏感性低(63.8%-71.1%),但特异性好(91.1%-96.2%)。我们得出的结论是,应该修改基于新办公室的幽门螺杆菌诊断单克隆酶免疫测定法,以提高敏感性,观察者间变异性和一些技术问题。相反,在治疗前后,单克隆EIA粪便测试是高度可靠的,相当于(13)C-尿素呼气测试。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号